Diwakar Jain1, Raymond R Russell2, Ronald G Schwartz3,4, Gurusher S Panjrath5, Wilbert Aronow6. 1. Section of Cardiovascular Medicine, New York Medical College and Westchester Medical Center, 100 Woods Road, Valhalla, NY, USA. dj2700@gmail.com. 2. Rhode Island Cardiovascular Institute, Rhode Island Hospital, The Warren Alpert Medical School of Brown University, Providence, RI, 02903, USA. 3. Cardiology Division, Department of Medicine, University of Rochester Medical Center, Rochester, NY, USA. 4. Nuclear Medicine Division, Department of Imaging Sciences, University of Rochester Medical Center, Rochester, NY, USA. 5. Heart and Vascular Institute, George Washington University School of Medicine and Health Sciences, Washington, DC, USA. 6. Section of Cardiovascular Medicine, New York Medical College and Westchester Medical Center, 100 Woods Road, Valhalla, NY, USA.
Abstract
PURPOSE OF REVIEW: Cardiotoxicity is an important complication of cancer therapy. With a significant improvement in the overall survival and prognosis of patients undergoing cancer therapy, cardiovascular toxicity of cancer therapy has become an important public health issue. Several well-established as well as newer anticancer therapies such as anthracyclines, trastuzumab, and other HER2 receptor blockers, antimetabolites, alkylating agents, tyrosine kinase inhibitors, angiogenesis inhibitors, checkpoint inhibitors, and thoracic irradiation are associated with significant cardiotoxicity. RECENT FINDINGS: Cardiovascular imaging employing radionuclide imaging, echocardiography, and magnetic resonance imaging is helpful in early detection of the cardiotoxicity and prevention of overt heart failure. These techniques also provide important tools for understanding the mechanism of cardiotoxicity of these modalities, which would help develop strategies for the prevention of cardiac morbidity and mortality related to the use of these agents. An understanding of the mechanism of the cardiotoxicity of cancer therapies can help prevent and treat their adverse cardiovascular consequences. Clinical implementation of algorithms based upon cardiac imaging and several non-imaging biomarkers can prevent cardiac morbidity and mortality associated with the use of cardiotoxic cancer therapies.
PURPOSE OF REVIEW: Cardiotoxicity is an important complication of cancer therapy. With a significant improvement in the overall survival and prognosis of patients undergoing cancer therapy, cardiovascular toxicity of cancer therapy has become an important public health issue. Several well-established as well as newer anticancer therapies such as anthracyclines, trastuzumab, and other HER2 receptor blockers, antimetabolites, alkylating agents, tyrosine kinase inhibitors, angiogenesis inhibitors, checkpoint inhibitors, and thoracic irradiation are associated with significant cardiotoxicity. RECENT FINDINGS: Cardiovascular imaging employing radionuclide imaging, echocardiography, and magnetic resonance imaging is helpful in early detection of the cardiotoxicity and prevention of overt heart failure. These techniques also provide important tools for understanding the mechanism of cardiotoxicity of these modalities, which would help develop strategies for the prevention of cardiac morbidity and mortality related to the use of these agents. An understanding of the mechanism of the cardiotoxicity of cancer therapies can help prevent and treat their adverse cardiovascular consequences. Clinical implementation of algorithms based upon cardiac imaging and several non-imaging biomarkers can prevent cardiac morbidity and mortality associated with the use of cardiotoxic cancer therapies.
Authors: Jonathan Walker; Navdeep Bhullar; Nazanin Fallah-Rad; Matthew Lytwyn; Mehrdad Golian; Tielan Fang; Arthur R Summers; Pawan K Singal; Ivan Barac; Iain D Kirkpatrick; Davinder S Jassal Journal: J Clin Oncol Date: 2010-06-07 Impact factor: 44.544
Authors: Nazanin Fallah-Rad; Jonathan R Walker; Anthony Wassef; Matthew Lytwyn; Sheena Bohonis; Tielan Fang; Ganhong Tian; Iain D C Kirkpatrick; Pawan K Singal; Marianne Krahn; Debjani Grenier; Davinder S Jassal Journal: J Am Coll Cardiol Date: 2011-05-31 Impact factor: 24.094
Authors: Greger Nilsson; Lars Holmberg; Hans Garmo; Olov Duvernoy; Iwar Sjögren; Bo Lagerqvist; Carl Blomqvist Journal: J Clin Oncol Date: 2011-12-27 Impact factor: 44.544
Authors: D D Von Hoff; M W Layard; P Basa; H L Davis; A L Von Hoff; M Rozencweig; F M Muggia Journal: Ann Intern Med Date: 1979-11 Impact factor: 25.391
Authors: Sui Zhang; Xiaobing Liu; Tasneem Bawa-Khalfe; Long-Sheng Lu; Yi Lisa Lyu; Leroy F Liu; Edward T H Yeh Journal: Nat Med Date: 2012-10-28 Impact factor: 53.440
Authors: R G Schwartz; W B McKenzie; J Alexander; P Sager; A D'Souza; A Manatunga; P E Schwartz; H J Berger; J Setaro; L Surkin Journal: Am J Med Date: 1987-06 Impact factor: 4.965
Authors: Tammy F Chu; Maria A Rupnick; Risto Kerkela; Susan M Dallabrida; David Zurakowski; Lisa Nguyen; Kathleen Woulfe; Elke Pravda; Flavia Cassiola; Jayesh Desai; Suzanne George; Jeffrey A Morgan; David M Harris; Nesreen S Ismail; Jey-Hsin Chen; Frederick J Schoen; Annick D Van den Abbeele; George D Demetri; Thomas Force; Ming Hui Chen Journal: Lancet Date: 2007-12-15 Impact factor: 79.321
Authors: Theresa H M Keegan; Lawrence H Kushi; Qian Li; Ann Brunson; X Chawla; Helen K Chew; Marcio Malogolowkin; Ted Wun Journal: J Cancer Surviv Date: 2018-02-09 Impact factor: 4.442
Authors: David Pérez-Callejo; María Torrente; María Auxiliadora Brenes; Beatriz Núñez; Mariano Provencio Journal: Med Oncol Date: 2017-08-09 Impact factor: 3.064
Authors: Anda Militaru; Adina Avram; Anca Maria Cimpean; Mircea Iurciuc; Petru Matusz; Daniel Lighezan; Marius Militaru Journal: In Vivo Date: 2018 Nov-Dec Impact factor: 2.155
Authors: Larissa Nekhlyudov; Grace B Campbell; Kathryn H Schmitz; Gabriel A Brooks; Anita J Kumar; Patricia A Ganz; Diane Von Ah Journal: Cancer Date: 2021-09-16 Impact factor: 6.921